TY - JOUR
T1 - Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy
T2 - A Comparative Analysis of Different Postoperative Management Strategies
AU - Touijer, Karim A.
AU - Karnes, Robert Jeffery
AU - Passoni, Niccolo
AU - Sjoberg, Daniel D.
AU - Assel, Melissa
AU - Fossati, Nicola
AU - Gandaglia, Giorgio
AU - Eastham, James A.
AU - Scardino, Peter T.
AU - Vickers, Andrew
AU - Cozzarini, Cesare
AU - Montorsi, Francesco
AU - Briganti, Alberto
N1 - Publisher Copyright:
© 2017 European Association of Urology
PY - 2018/6
Y1 - 2018/6
N2 - Background: Optimal management of patients with lymph node metastasis (LNM) after radical prostatectomy (RP) remains undefined. Objective: We evaluated the association between three different management strategies and survival in prostate cancer with LNM after RP. Design, setting, and participants: We analyzed data of 1338 patients with LNM after RP from three tertiary care centers. Three hundred and eighty-seven patients (28%) were observed, 676 (49%) received lifelong adjuvant androgen deprivation therapy (ADT), and 325 (23%) received adjuvant external beam radiation therapy (EBRT) and ADT. Three hundred and sixty-eight men were followed for more than 10 yr. Outcome measurements and statistical analysis: Primary outcome measure was overall survival (OS). Secondary outcomes were cancer-specific survival (CSS) and other-cause mortality. Kaplan-Meier methods were used to visualize OS for the three treatment groups. Cox proportional hazards regression was utilized to compare OS and CSS among the three groups. Results and limitations: ADT + EBRT was associated with better OS than ADT alone (hazard ratio [HR]: 0.46, 95% confidence interval [CI]: 0.32–0.66, p < 0.0001) or observation (HR: 0.41, 95% CI: 0.27–0.64, p < 0.0001). Higher-risk patients benefited more from ADT + EBRT than lower-risk patients. Ten-year mortality risk difference between ADT + EBRT, observation, or ADT alone ranged from 5% in low-risk patients to 40% in high-risk patients. Adjuvant ADT + EBRT was also associated with better CSS than observation or ADT alone (p < 0.0001), ADT had better CSS compared to observation (HR: 0.64, 95% CI: 0.43–0.95, p = 0.027). However, ADT was associated with an increased risk of other-cause mortality (HR: 3.05, 95% CI: 1.45–6.40, p = 0.003) compared with observation, resulting in similar OS between ADT and observation (HR: 0.90, 95% CI: 0.65–1.25, p = 0.5). While selection bias might remain, its effect would operate in the opposite direction to our findings. Conclusions: In men with LNM after RP, ADT + EBRT improved survival over either observation or adjuvant ADT alone. This survival benefit increases with higher-risk disease. Patient summary: Lymph node metastasis following radical prostatectomy is associated with poor survival outcomes. However, we found that adjuvant androgen deprivation therapy with external beam radiation therapy improved survival in these patients. Lymph node metastasis following radical prostatectomy is associated with poor survival outcomes. Adjuvant androgen deprivation therapy with external beam radiation therapy confers a long-term overall survival advantage than either observation or androgen deprivation therapy alone.
AB - Background: Optimal management of patients with lymph node metastasis (LNM) after radical prostatectomy (RP) remains undefined. Objective: We evaluated the association between three different management strategies and survival in prostate cancer with LNM after RP. Design, setting, and participants: We analyzed data of 1338 patients with LNM after RP from three tertiary care centers. Three hundred and eighty-seven patients (28%) were observed, 676 (49%) received lifelong adjuvant androgen deprivation therapy (ADT), and 325 (23%) received adjuvant external beam radiation therapy (EBRT) and ADT. Three hundred and sixty-eight men were followed for more than 10 yr. Outcome measurements and statistical analysis: Primary outcome measure was overall survival (OS). Secondary outcomes were cancer-specific survival (CSS) and other-cause mortality. Kaplan-Meier methods were used to visualize OS for the three treatment groups. Cox proportional hazards regression was utilized to compare OS and CSS among the three groups. Results and limitations: ADT + EBRT was associated with better OS than ADT alone (hazard ratio [HR]: 0.46, 95% confidence interval [CI]: 0.32–0.66, p < 0.0001) or observation (HR: 0.41, 95% CI: 0.27–0.64, p < 0.0001). Higher-risk patients benefited more from ADT + EBRT than lower-risk patients. Ten-year mortality risk difference between ADT + EBRT, observation, or ADT alone ranged from 5% in low-risk patients to 40% in high-risk patients. Adjuvant ADT + EBRT was also associated with better CSS than observation or ADT alone (p < 0.0001), ADT had better CSS compared to observation (HR: 0.64, 95% CI: 0.43–0.95, p = 0.027). However, ADT was associated with an increased risk of other-cause mortality (HR: 3.05, 95% CI: 1.45–6.40, p = 0.003) compared with observation, resulting in similar OS between ADT and observation (HR: 0.90, 95% CI: 0.65–1.25, p = 0.5). While selection bias might remain, its effect would operate in the opposite direction to our findings. Conclusions: In men with LNM after RP, ADT + EBRT improved survival over either observation or adjuvant ADT alone. This survival benefit increases with higher-risk disease. Patient summary: Lymph node metastasis following radical prostatectomy is associated with poor survival outcomes. However, we found that adjuvant androgen deprivation therapy with external beam radiation therapy improved survival in these patients. Lymph node metastasis following radical prostatectomy is associated with poor survival outcomes. Adjuvant androgen deprivation therapy with external beam radiation therapy confers a long-term overall survival advantage than either observation or androgen deprivation therapy alone.
KW - Adjuvant radiotherapy
KW - Antineoplastic agents
KW - Hormonal
KW - Lymphatic metastasis
KW - Mortality
KW - Prognosis
KW - Prostatectomy
KW - Prostatic neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85031424397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031424397&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2017.09.027
DO - 10.1016/j.eururo.2017.09.027
M3 - Article
C2 - 29042125
AN - SCOPUS:85031424397
SN - 0302-2838
VL - 73
SP - 890
EP - 896
JO - European urology
JF - European urology
IS - 6
ER -